Variations in DNA methylation of interferon gamma and programmed death 1 in allograft rejection after kidney transplantation by Boer, K. (Karin) et al.
RESEARCH Open Access
Variations in DNA methylation of interferon
gamma and programmed death 1 in
allograft rejection after kidney
transplantation
Karin Boer1*, L. Elly A. de Wit1, Fleur S. Peters1, Dennis A. Hesselink1, Leo J. Hofland2, Michiel G. H. Betjes1,
Caspar W. N. Looman3 and Carla C. Baan1
Abstract
Background: The role of DNA methylation in the regulation of the anti-donor-directed immune response after
organ transplantation is unknown. Here, we studied the methylation of two mediators of the immune response: the
pro-inflammatory cytokine interferon γ (IFNγ) and the inhibitory receptor programmed death 1 (PD1) in naïve and
memory CD8+ T cell subsets in kidney transplant recipients receiving immunosuppressive medication. Both
recipients experiencing an episode of acute allograft rejection (rejectors) as well as recipients without rejection
(non-rejectors) were included.
Results: CpGs in the promoter regions of both IFNγ and PD1 were significantly (p < 0.001) higher methylated in the
naïve CD8+ T cells compared to the memory T cell subsets. The methylation status of both IFNγ and PD1 inversely
correlated with the percentage of IFNγ or PD1-producing cells. Before transplantation, the methylation status of both
IFNγ and PD1 was not significantly different from healthy donors. At 3 months after transplantation, irrespective of
rejection and subsequent anti-rejection therapy, the IFNy methylation was significantly higher in the differentiated
effector memory CD45RA+ (EMRA) CD8+ T cells (p = 0.01) whereas the PD1 methylation was significantly higher in all
memory CD8+ T cell subsets (CD27+ memory; p = 0.02: CD27− memory; p = 0.02: EMRA; p = 0.002). Comparing the
increase in methylation in the first 3 months after transplantation between rejectors and non-rejectors demonstrated a
significantly more prominent increase in the PD1 methylation in the CD27− memory CD8+ T cells in rejectors (increase
in rejectors 14%, increase in non-rejectors 1.9%, p = 0.04). The increase in DNA methylation in the other memory CD8+
T cells was not significantly different between rejectors and non-rejectors. At 12 months after transplantation, the
methylation of both IFNγ and PD1 returned to baseline levels.
Conclusions: The DNA methylation of both IFNγ and PD1 increases the first 3 months after transplantation in memory
CD8+ T cells in kidney transplant recipients. This increase was irrespective of a rejection episode indicating that general
factors of the kidney transplantation procedure, including the use of immunosuppressive medication, contribute to
these variations in DNA methylation.
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Background
Kidney transplantation is currently the best treatment
option for patients with irreversible, end-stage kidney
disease [1]. Successful kidney transplantation is hampered
by different complications including immune-mediated
complications such as acute rejection [2]. Several non-
invasive biomarkers for acute rejection have been studied,
including proteins involved in cytotoxic lymphocyte func-
tion (e.g., perforin and granzyme B), cytokines (e.g., inter-
feron (IFN) γ), and immune-related chemokines (e.g.,
CXCL9 and CXCL10) [3, 4]. Nevertheless, it remains diffi-
cult to predict and regulate the host immune response
after transplantation. The host immune response is
orchestrated by a tightly regulated cascade of gene expres-
sion changes which are regulated by epigenetic mecha-
nisms like histone modifications, DNA methylation,
microRNA interactions, and chromatin remodeling com-
plexes [5–8]. Variations in these epigenetic mechanisms
might serve as an additional marker to monitor the host
immune response after organ transplantation.
An important player of the host immune response is
the pro-inflammatory cytokine IFNγ, and high expres-
sion of IFNγ is associated with both acute and chronic
allograft rejection [9–11]. The expression of IFNγ is reg-
ulated by DNA methylation with the addition of methyl
groups on cytosine-phosphate-guanine sites (CpGs) in
the IFNγ promoter region silencing its expression. The
CpG methylation pattern of IFNy discriminates different
T cell subsets. First, naïve (antigen unexperienced) T cells
versus memory (antigen experienced) T cells (both CD4+
and CD8+ T cells) with memory T cells having a lower
methylation profile [12–14]. Second, the different T helper
cell (Th) subsets with Th1 cells being hypomethylated
compared to the Th2 and Th17 subsets [15–17]. Another
important molecule involved in the regulation of the anti-
donor immune response is the inhibitory receptor pro-
grammed cell death (PD) 1. Aggressive recipient T cells
that attack the transplanted organ, the so-called alloreac-
tive T cells, are inhibited by PD1 signaling. In addition,
PD1 signaling promotes the generation of induced regula-
tory T cells [18, 19]. The expression of PD1 is also
dependent on DNA methylation and while mainly methyl-
ated in naïve T cells, PD1 is demethylated during differen-
tiation into memory T cells [20].
Regulation of gene expression by DNA methylation is
a well-known epigenetic mechanism with a critical role
in physiological development and normal cell function
by coordinating the lineage- and tissue-specific expres-
sion of genes [21]. DNA methylation is dynamic and
susceptible to stimuli from the environment including
internal stimuli like cytokines and hormones and exter-
nal stimuli like chemical agents, pollutants, dietary com-
ponents, and chronic viral infections [16, 22–24].
Aberrant DNA methylation profiles are associated with
the pathogenesis of disease. Initially, DNA methylation
was associated with tumor formation and progression
[25], but later on, variations in DNA methylation have
been associated with other diseases [26, 27] including
chronic kidney disease (CKD) [28, 29] and immune-
mediated diseases such as rheumatoid arthritis [30] and
allergy [31, 32]. In addition, variations in DNA methyla-
tion of immune-related genes orchestrate the host im-
mune response after organ transplantation [5–8].
Graft-infiltrating cytotoxic CD8+ T cells play a major
role in the rejection process and elevated numbers of ef-
fector, and memory CD8+ Tcell subsets are associated with
an increased risk for acute rejection [33–35]. Here, we ex-
amined the influence of variations in DNA methylation of
IFNγ and PD1 in different CD8+ T cell subsets on allograft
rejection. The DNA methylation of IFNγ and PD1 was de-
termined in kidney transplant recipients before and 3 and
12 months after transplantation, and both kidney transplant
recipients who experienced a rejection episode within the
first 3 months after transplantation and recipients who
remained free from rejection were included. To exclude
gender- [32] or chronic viral infection [24]-related differ-
ences, we first analyzed whether the DNA methylation of
either IFNγ or PD1 was different in males versus females or
in cytomegalovirus (CMV) seropositive healthy donors ver-
sus CMV seronegative healthy donors.
Results
IFNγ methylation is significantly decreased in CMV
seropositive individuals
In PBMCs of CMV seronegative healthy donors, the
DNA methylation of IFNy was 51.2 ± 4.4% (mean ± SD).
The IFNy methylation was significantly lower in PBMCs
of age-matched CMV seropositive healthy kidney donors
(45.1 ± 7.2%, p = 0.009; Fig. 1a). In both males and females,
the methylation of IFNy was lower in the CMV seropositive
individuals (Fig. 1a), and there was no significant difference
between males and females. The DNA methylation of PD1
in PBMCs of CMV seronegative healthy donors was com-
parable to the PD1 methylation in CMV seropositive
healthy donors (40.5 ± 5.3 versus 38.9 ± 6.3%; Fig. 1b). Sub-
dividing the PBMCs into the different CD8+ T cell subsets
(Fig. 1c) demonstrated significantly lower methylation of
IFNγ in naïve, CD27+ memory, and CD27− memory CD8+
T cells in CMV seropositive individuals compared to CMV
seronegative individuals (Fig. 1d). The methylation of PD1
was not significantly different between the CMV seroposi-
tive individuals and CMV seronegative individuals in all the
studied CD8+ Tcell subsets (Fig. 1e).
DNA methylation inversely correlates with protein
expression
To determine whether variations in DNA methylation at
the described CpGs [20, 36] are associated with changes
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in protein expression, we measured the expression of
IFNγ and PD1 in the different CD8+ T cell subsets
(Fig. 2a). A clear-cut difference was observed between
the naïve CD8+ T cells compared to the memory CD8+
T cells where 14.6 ± 16.4% (mean ± SD) of naïve CD8+ T
cells expressed IFNγ versus 50.3 ± 18.9% of the CD27+
memory, 52.6 ± 20.6% of the CD27− memory and 66.1 ±
19.8% of the EMRA CD8+ T cells expressed IFNγ (p <
0.0001; Fig. 2b). In parallel, a significantly lower percent-
age of naïve CD8+ T cells expressed PD1 compared to
the memory CD8+ T cell subsets (naïve 27.3 ± 16.5%,
CD27+ memory 67.9 ± 5.1%, CD27− memory 68.4 ±
12.2%, and EMRA 51.4 ± 20.1; p < 0.0001; Fig. 2e). The
highest percentage of IFNγ-expressing cells was found
within the EMRA CD8+ T cells while the CD27+ and
CD27− memory CD8+ T cell subsets contained the
highest percentages of PD1-expressing cells. The DNA
methylation of both IFNγ and PD1 demonstrated the
opposite pattern with the highest percentage of methyla-
tion in naïve CD8+ T cells. Naïve CD8+ T cells were
methylated for 55.2 ± 18.3% at the IFNγ locus and for
43.1 ± 10.7% at the PD1 locus. This methylation was sig-
nificantly higher (p < 0.0001 for both IFNγ and PD1)
compared to the different memory CD8+ T cell subsets
(Fig. 2c, f ). This inverse relation between the DNA
methylation and protein expression confirms the regula-
tory capacity of the studied CpGs (Fig. 2d, g).
Variations in DNA methylation in kidney transplant
recipients before transplantation
Before kidney transplantation, the methylation of IFNγ in
CMV seronegative kidney recipients was comparable to the
Fig. 1 IFNγ and PD1 methylation in CMV seropositive and CMV seronegative healthy kidney donors. The percentage of DNA methylation of IFNγ
(a) and of PD1 (b) in CMV seronegative (n = 15; open bars) and CMV seropositive healthy donors (n = 15; gray bars) in PBMCs (mean ± SD) and
stratified by gender (box and whiskers min to max). Gating strategy of the different CD8+ memory T cell subsets in (c). The percentage of DNA
methylation of IFNγ (d) and of PD1 (e) in CMV seropositive (n = 5; open bars) and CMV seronegative healthy donors (n = 5; gray bars) in cell sorted
CD8+ T cell subsets; naïve, CD27+ memory, CD27− memory, and differentiated effector memory CD45RA+ (EMRA). Box and whiskers (min to
max); *p < 0.05 and **p < 0.01
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methylation levels in CMV seronegative healthy donors for
naïve, CD27+ memory, CD27− memory, and EMRA CD8+
T cells (Fig. 3a). The same pattern was seen for the methy-
lation of PD1 (Fig. 3b). Subdividing the transplant recipi-
ents into the ones that went on to experience a rejection
after transplantation, the rejectors and the non-rejectors,
did not reveal any significant differences in methylation of
IFNγ nor PD1, either between the two recipient groups or
in comparison to the healthy donors (data not shown).
Variations in DNA methylation in kidney transplant
recipients after transplantation
After kidney transplantation, the percentage of methyla-
tion of IFNγ did not change significantly in the naïve,
Fig. 2 IFNγ and PD1 protein expression and IFNγ and PD1 DNA methylation. FACS plots of IFNγ and PD1 expression in naïve, CD27+ memory,
CD27− memory, and differentiated effector memory CD45RA+ (EMRA) CD8+ T cells in (a; representative example). Mean protein expression and
percentage of DNA methylation in the different CD8+ T cell subsets in kidney transplant recipients before transplantation (n = 10; IFNγ in b–d
and PD1 in e–g; mean ± SD). ***p < 0.001
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CD27+ memory, and CD27− memory CD8+ T cells dur-
ing the first year after transplantation (Fig. 4a–c). In the
EMRA CD8+ T cells, the methylation of IFNγ was sig-
nificantly higher at 3 months after transplantation com-
pared to the methylation before transplantation
irrespective of rejection and the subsequent anti-
rejection therapy (p = 0.01; Fig. 4d). Focusing on rejec-
tion demonstrated that the methylation of IFNγ was sig-
nificantly higher at 3 months after transplantation in the
rejectors (14.3% versus 6.3% before transplantation; p =
0.01) while the non-rejectors increased from 4.9 to 8.6%
(not significant). Both rejectors and non-rejectors dem-
onstrated elevated IFNγ methylation levels in the EMRA
CD8+ T cells at 3 months after transplantation, but this
increase in methylation was not significantly different
between rejectors and non-rejectors (p = 0.3). At 1 year
after transplantation, the methylation of IFNγ was com-
parable to the levels measured before transplantation.
The methylation of PD1 did not change significantly
in the naïve CD8+ T cells during the first year after
transplantation (Fig. 4e). Irrespective of rejection, the
methylation of PD1 significantly increased during the
first 3 months after transplantation in CD27+ memory
CD8+ T cells with 7.2% (p = 0.02), in CD27− memory
CD8+ T cells with 7.9% (p = 0.02), and in EMRA CD8+ T
cells with 7.5% (p = 0.002; Fig. 4f–h)). Focusing on rejec-
tion demonstrated a more prominent increase in DNA
methylation in the rejectors compared to the non-
rejectors in all memory CD8+ T cell subsets (CD27+
memory: rejectors 27.8 versus 17.6%, p = 0.02 and non-
rejectors 18.9 versus 14.6% p = 0.3; CD27− memory: rejec-
tors 25.4 versus 11.4%, p = 0.002 and non-rejectors 12.7
versus 10.9%, p = 0.6; EMRA: rejectors 23.8 versus 13.2%,
p = 0.002 and non-rejectors 16.5 versus 12.1%, p = 0.2;
methylation at 3 months versus before transplantation, re-
spectively). The increase in PD1 methylation in rejectors
during the first 3 months after transplantation was not
significantly different from the increase in PD1 methyla-
tion in non-rejectors in both the CD27+ memory CD8+ T
cells (p = 0.3) and EMRA CD8+ T cells (p = 0.2). In the
CD27− memory CD8+ T cells, the increase in PD1
methylation was significantly higher in the rejectors (14%)
compared to the non-rejectors (1.9%, p = 0.04). In parallel
with the methylation of IFNγ, the methylation of PD1
returned to normal levels at 1 year after transplantation.
Discussion
The clinical potential of DNA methylation in organ
transplantation, either as diagnostic or prognostic bio-
marker or as therapeutic target has been proposed by
many [5–8, 37, 38]. Nevertheless, this is the first study
where DNA methylation of two selected genes, IFNγ
and PD1, was actually studied in CD8+ T cells in a small
cohort of human kidney transplant recipients over time
in relation to acute allograft rejection. Irrespective of re-
jection, we observed at 3 months after transplantation
significantly elevated DNA methylation levels of IFNγ in
the differentiated EMRA CD8+ T cells, while the DNA
methylation of PD1 was significantly higher in all CD8+
memory T cell subsets. This increase in IFNγ methyla-
tion was not significantly different between rejectors and
non-rejectors, while the increase in PD1 methylation
was significantly higher in the rejectors in the CD27−
memory CD8+ T cells. In the other CD8+ memory T
cells subsets (CD27+ memory and EMRA), the increase
in DNA methylation of PD1 was not significantly differ-
ent between rejectors and non-rejectors.
Kidney transplantation will activate the recipient’s im-
mune system accompanied by an increase in cytokine pro-
duction, including production of the pro-inflammatory
IFNγ [35, 39, 40], and upregulation of PD1 expression
[41]. As protein expression inversely correlates with DNA
methylation levels at gene promoter sites, kidney trans-
plantation induces demethylation of genes involved in im-
mune activation. However, for both IFNγ and PD1, an
increase in DNA methylation was observed in rejectors
and non-rejectors in the first 3 months after transplant-
ation, indicative for lower expression levels of IFNγ and
PD1. Likely, the expected demethylation is only detectable
in the donor-antigen specific T cells. The low percentage
of these cells within the selected CD8+ T cells explains
why the expected decrease in methylation was not
Fig. 3 IFNγ and PD1 methylation in healthy donors and kidney transplant recipients before transplantation. The percentage of DNA methylation
of IFNγ (a) and PD1 (b) in healthy controls (HC; n = 5; open bars) and kidney transplant recipients before transplantation (preTx; n = 10; gray bars)
in cell sorted CD8+ T cell subsets; naïve, CD27+ memory, CD27− memory, and differentiated effector memory CD45RA+ (EMRA). Box and whiskers
(min to max)
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observed. The observed increase in IFNγ and PD1 DNA
methylation most likely does not reflect the immune re-
sponse against the foreign donor antigen but demon-
strates a downregulation of the immune system achieved
by the given immunosuppressive medication which non-
specifically block all T cell subsets. For example, the usage
of prednisolone. In this study, prednisolone was tapered
to 5 mg at month 3 and thereafter completely withdrawn.
At 1 year after transplantation, the DNA methylation
levels returned to baseline.
In a clinical transplantation setting, it is impossible to
measure the DNA methylation of either IFNγ or PD1
just before rejection. Currently, rejection cannot be pre-
dicted as the moment of rejection strongly varies be-
tween individuals and therefore those samples are not
available. Although the material was only available of a
small number of patients, we had the unique opportun-
ity to follow the same patients over time. Variations in
DNA methylation are more profoundly found in the
period after withdrawal of stress exposure (e.g., drugs)
compared to the period during exposure [42, 43]. Trans-
lation to the field of organ transplantation implies that
after a rejection episode including anti-rejection therapy,
rejectors would have more variations in DNA methyla-
tion compared to non-rejectors. However, this was not
true for the methylation of either IFNγ or PD1 at
12 months after transplantation, indicating that allograft
rejection has no imprinted effect on the DNA methyla-
tion of those immune genes.
Despite differences in immune activity of the distinct
memory CD8+ T cell subsets, the variations in DNA
methylation in either memory subset were comparable.
Fig. 4 IFNγ and PD1 methylation in kidney transplant recipients during the first year after transplantation. The percentage of DNA methylation of
IFNγ (a–d) and of PD1 (e–h) in kidney transplant recipients before and 3 and 12 months after transplantation in cell sorted CD8+ T cell subsets;
naïve (a, e), CD27+ memory (b, f), CD27− memory (c, g), and differentiated effector memory CD45RA+ (EMRA; d, h). *p < 0.05 and **p < 0.01
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The EMRA CD8+ T cells are potentially the most ag-
gressive subtype with a strong cytolytic activity, while
the CD27+ memory cells display weak cytolytic activity
producing effector cytokines such as interleukin (IL) 2,
IFNγ, tumor necrosis factor (TNF) α, and IL4 [44, 45].
The CD27− memory CD8+ T cells, which are function-
ally in between the CD27+ memory CD8+ T cells and
the EMRA CD8+ T cells, represent the smallest subpopu-
lation and it is unclear why specifically these cells demon-
strated a significant difference in increase in methylation
of PD1 between rejectors and non-rejectors.
DNA methylation is adjustable by cues from the environ-
ment, e.g., viral infections [20, 24, 46], though the exact
cues and mechanisms remain largely unknown [16, 22, 23].
The uremic condition during chronic kidney disease (CKD)
modifies DNA methylation profiles [47–49]. Although, be-
fore transplantation, we did not observe significant changes
in the methylation of either PD1 or IFNγ compared to age-
matched healthy donors. Either the previously observed
effect on DNA methylation is gene specific and not applic-
able to IFNy and PD1 or the included transplant recipients
here had less severe kidney disease compared to the CKD
patients studied previously.
In contrast to previous observations where males dem-
onstrated a significantly higher DNA methylation of
IFNγ compared to females [32], significant differences in
DNA methylation between males and females were not
observed. However, we observed a significantly lower %
of IFNγ methylation in CMV seropositive healthy donors
compared to CMV seronegative healthy donors. The ef-
fect of chronic CMV infection on DNA methylation is
not documented yet, but the change of the composition
of the T cell pool with a permanent increase in highly
differentiated T cells with a more memory phenotype in
CMV seropositive individuals [50] has been demon-
strated repeatedly. Therefore, the lower % of IFNγ
methylation in CMV seropositive individuals might be
explained by the fact that memory T cells are less meth-
ylated at the IFNγ locus (Fig. 2 and [12–14]). Neverthe-
less, also in selected CD8+ memory T cells, the
methylation of IFNγ was significantly lower in the CMV
seropositive individuals (Fig. 1), indicating that CMV in-
fection not only affects the composition of the T cell
compartment but also induces a more aggressive T cell
phenotype since demethylation is associated with an in-
creased IFNγ production.
Although we could not identify variations in DNA
methylation of either IFNy or PD1 in CD8+ T cells
which could either diagnose or predict allograft rejection
after kidney transplantation, further research is needed
to appreciate the clinical significance of variations in
DNA methylation and other epigenetic mechanisms in
kidney transplantation. Epigenetic biomarkers, mainly
based on variations in DNA methylation, are well
established in the diagnosis of cancer and are not only
detectable in the affected tissue as well as in the urine or
the peripheral blood [51, 52]. Currently, the application
of epigenetic biomarkers is extended to other complex
diseases such as autoimmune diseases [30, 53, 54]. The
increasing knowledge on the epigenetic regulation of im-
mune cells will contribute to our understanding of the
epigenetic regulation of the complex anti-donor immune
response after kidney transplantation. Epigenetic varia-
tions precede changes in protein expression and cell
function and thereby represent an early indicator of clin-
ical complications. Accordingly, a more comprehensive
understanding of the epigenetic regulation of the anti-
donor immune response will learn whether variations in
DNA methylation can serve as predictive, diagnostic, or
prognostic markers. Moreover, since DNA methylation
is influenced by environmental cues, it might serve as a
target for therapeutic intervention.
A genome-wide approach instead of selected immuno-
regulatory genes are a good option for future research.
Genome-wide analysis enables the identification of varia-
tions in DNA methylation in all promoter regions as
well as other gene regions including intragenic and
intergenic regions [47, 55, 56]. Since DNA methylation
profiles are cell-type specific [57], selected cell subsets
involved in the anti-donor immune response (e.g., CD4+
T cell subsets, B cells, and macrophages), or even better
the donor-antigen specific cells, should be analyzed. An-
other interesting, though technically more challenging
option, is to analyze variations in DNA methylation in
graft-infiltrating T cells. As variations in DNA methyla-
tion occur specifically in donor-antigen specific cells
which are more abundantly present in the graft com-
pared to the circulation.
Conclusions
After kidney transplantation, the DNA methylation of
the promoter of both IFNγ and PD1 increases in the first
3 months and returns to baseline at 1 year after trans-
plantation irrespective of rejection. These variations do
not reflect the anti-donor immune response but are
more likely the result of the transplantation procedure
and the use of immunosuppressive medication.
Methods
Study population
Prior to the selection of kidney transplant recipients, we
first determined whether cytomegalovirus (CMV) infec-
tion modulates DNA methylation of either IFNγ or PD1.
Peripheral blood mononuclear cells (PBMCs) of 15
CMV seropositive healthy donors (age 52 years, range
38–71; 5 males and 10 females) and 15 age-matched
CMV seronegative healthy donors (age 52 years, range
44–59; 11 males and 4 females) were studied. Of these
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30 healthy donors in total, we selected 5 CMV seroposi-
tive and 5 CMV seronegative age-matched individuals to
study the methylation status in different CD8+ T cell
subsets. Based on the significant decrease in DNA
methylation of IFNγ in CMV seropositive healthy do-
nors, we included only CMV seronegative kidney trans-
plant recipients who received their first kidney from a
living donor. The DNA methylation of both IFNγ and
PD1 was examined in different CD8+ T cell subsets in 5
recipients who developed a biopsy-proven acute cellular
rejection within the first 3 months after transplantation
(rejectors; Table 1) and 5 age-matched recipients who
remained free from rejection the first year after trans-
plantation (non-rejectors) and was compared to 5 age-
matched healthy donors (age 54 years, range 44–59).
The different CD8+ T cell subsets were analyzed at dif-
ferent time points; before transplantation and 3 and
12 months after transplantation. The selected CMV
seronegative recipients all received a kidney from a
CMV seronegative donor and received basiliximab as in-
duction therapy. After transplantation, recipients received
standard triple maintenance therapy consisting of prednis-
olone (tapered after 3 months), mycophenalate mofetil
(MMF), and tacrolimus. Anti-rejection therapy consisted
of methylprednisolone (1 g per day) on three consecutive
days followed in some cases by anti-thymocyte globulin
(ATG; n = 2) or alemtuzumab (n = 1).
Isolation of peripheral blood mononuclear cells and CD8+
T cell subsets
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from heparinized blood samples by density gradient
centrifugation using standard Ficoll-Paque (GE Health-
care, Uppsala, Sweden) procedures. Since DNA methyla-
tion profiles are cell type specific [57], we examined naïve
(antigen unexperienced; CD27+CD45RA+) CD8+ T cells
and memory (antigen experienced) CD8+ T cells separ-
ately. The memory CD8+ T cells were subdivided into the
differentiated effector memory CD8+ T cells (EMRA:
CD27-CD45RA+, with a strong cytolytic activity), CD27+
memory T cells (CD27+CD45RA−; with weak cytolytic
potential), and CD27− memory T cells (CD27-CD45RA−;
functionally in between CD27+ memory CD8+ T cells and
EMRA CD8+ T cells) [44, 45]. The different CD8+ T cell
subsets were isolated using cell sorting (BD FACSAria™ II
SORP, BD Biosciences, San Jose, CA, USA) with a mean
purity of 96%. Total PBMCs were stained with the follow-
ing monoclonal antibodies: Brilliant Violet 510™-labeled
CD3 (Biolegend, San Diego, CA, USA), APC-Cy7-labeled
CD8 (BD), PE-Cy7-labeled CD27 (eBioscience, San
Diego), APC-labeled CD45RA (BD), and 7-amino-
actinomycin D (7-AAD, BD) for the exclusion of nonvia-
ble cells.
Bisulfite conversion
PBMCs and the FACS-sorted CD8+ T cell subsets were
digested with proteinase K and treated with bisulfite
using the EZ DNA Methylation-Direct Kit (Zymo Re-
search from Base Clear Lab products, Leiden, The
Netherlands), according to the manufacturer’s instruc-
tions. During bisulfite treatment, unmethylated cytosines
were converted into uracil, whereas methylated cytosines
remained unchanged.
PCR amplification and pyrosequencing
The DNA methylation of the IFNγ promoter was deter-
mined at two CpGs (CpG-186 and CpG-54) with tran-
scription factor activity [36], and for PD1, eight
previously described [20] CpG sites ranging between
−914 and −738 bp from the start codon were studied
(CpG-914, CpG-911, CpG-906, CpG-857, CpG-833,
CpG-776, CpG-762, and CpG-738). Since the methyla-
tion status at adjacent CpGs is correlated [58], the mean
% of methylation of either IFNγ or PD1 was calculated.
Primers for PCR and pyrosequencing were designed
using PyroMark Assay Design 2.0 software (Qiagen,
Venlo, The Netherlands; Table 2).
PCR amplifications were performed with the Pyromark
PCR Kit from Qiagen with each primer in a concentra-
tion of 0.2 μM. The PCR conditions were 15 min at 95 °
C, 45 cycles of 30 s 94 °C, 30 s 58 °C for IFNγ and 56 °C
for PD1 and 30 s 72 °C followed by 10 min at 72 °C and
on hold at 21 °C. After visualization of the appropriately
sized PCR product on a 1% agarose gel, the PCR product
was sequenced using a PyroMark Q24 pyrosequencer
(Qiagen) with the following minor revisions to the man-
ufacturer’s instructions: to immobilize the PCR product,
1 μl Streptavidin Sepharose High Performance Beads
(GE Healtcare) were used per sequence reaction and
Table 1 Clinical characteristics of kidney transplant recipients
Rejectors Non-rejectors
No. of subjects 5 5
Age at transplantation (year)a 47 (43–54) 52 (44–66)
Gender (M/F) 4/1 5/0
Serum creatinin (μmol/l)a,b 480 (270–1484) 532 (374–682)
Underlying kidney disease
HN/PKD/other 3/1/1 0/4/1
Renal replacement therapy
HD/PD/pre-emptive 1/2/2 1/1/3
Number of HLA-A/B mismatchesc 2.2 ± 0.4 2.8 ± 0.8
Number of HLA-DR mismatchesc 2.0 ± 0 1.0 ± 0.7
HN hypertensive nephropathy, PKD polycystic kidney disease, HD hemodialysis,
PD peritoneal dialysis
aMedian with range
bBefore transplantation
cMean ± SD
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annealing of the sequence primers was done for 3 min
at 80 °C. The bisulfite conversion and the subsequent
PCR amplification and pyrosequencing were performed
in duplicate. Human low and high methylated DNA
from EpigenDx (Hopkinton, MA, USA) were used as
controls.
IFNγ and PD1 protein expression
To determine IFNγ and PD1 protein production by the
different CD8+ T cell subsets, total PBMCs were either
not stimulated or stimulated in the presence of 1 μg/ml
Brefeldin A (GolgiPlug; BD Biosciences) with PMA
(50 ng/ml, Sigma-Aldrich, St. Louis, MO, USA) and
ionomycin (1 μg/ml, Sigma-Aldrich) for 4 h at 37 °C in
5% CO2. For IFNγ, cells were stained for 30 min for the
following surface markers: Brilliant Violet 510™-labeled
CD3 (Biolegend), APC-Cy7-labeled CD8 (BD Biosci-
ences), PE-Cy7-labeled CD27 (eBioscience), APC-labeled
CD45RA (BD Biosciences), and 7-amino-actinomycin D
(7-AAD, BD Biosciences), fixed, permeabilized, and
stained with FITC-labeled IFNγ (BD Biosciences) for
30 min. Frequencies of IFNγ-producing CD8+ T cell
subsets were corrected for background determined with
the unstimulated condition. For PD1, cells were stained
with the previously described surface markers while PE-
labeled PD1 (Biolegend) was added. For PD1 expression,
a Fluorescence Minus One (FMO) was used to correct
for background staining. Samples were measured on the
FACSCanto II (BD) and analyzed using FACSDiva soft-
ware version 6.1.2. (BD).
Statistical analysis
To identify differences between groups, the unpaired t
test, Mann-Whitney U test, and ANOVA were used as
appropriate. To determine differences after kidney trans-
plantation over time between rejectors and non-
rejectors, we used multilevel analysis with the percent-
age of DNA methylation as outcome. Predictors were
different individuals (rejectors and non-rejectors), time
also as categorical predictor (levels 0 (before transplant-
ation), 3 and 12 months after transplantation), and indi-
viduals as random intercept. Each model was applied for
the four different cell types studied; naïve, CD27+ mem-
ory, CD27− memory, and EMRA CD8+ T cell subsets.
Afterwards, we added models with interaction between
type of individual and time. The first model describes
the same pattern over time for both rejectors and
non-rejectors while the second one enables to esti-
mate and test different trends in time for rejectors
and non-rejectors. The estimates and standard errors
were transformed to CI’s and p values. We used the pack-
age R version 3.1.2 and libraries lmer and lmerTest. A
p value of <0.05 was considered statistically significant.
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